Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development
Source: SeekingAlpha
2025-11-19 15:01:02 ET
The last time I spoke about Enanta Pharmaceuticals, Inc. ( ENTA ) it was in a Seeking Alpha article entitled "Enanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design Change." I noted then that this company had failed to meet the primary endpoint of the phase 2b randomized RSVHR study, which was time to resolution of the lower respiratory tract disease [LRTD] of 4 symptoms....
Read the full article on Seeking Alpha
For further details see:
Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development
Celldex Therapeutics Inc.
NASDAQ: CLDX
CLDX Trading
5.31% G/L:
$30.445 Last:
591,333 Volume:
$29.21 Open:
CLDX Latest News
February 27, 2026 02:45:00 pm
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAA
February 25, 2026 04:01:00 pm
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
CLDX Stock Data
$1,661,236,775
63,525,694
0.16%
57
N/A
Biotechnology & Life Sciences
Healthcare
US
Hampton
